Jasper Therapeutics, Inc.
JSPR · Nasdaq · United States
Share price · JSPR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when JSPR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+11.4%
Nothing announced by JSPR that day or the session before.
- 17 Nov 2026-12.1%
- 16 Nov 2026-14.0%
- 6 Nov 2026+19.8%
Nothing announced by JSPR that day or the session before.
- 14 Jul 2026+18.9%
Nothing announced by JSPR that day or the session before.
- 29 Jun 2026+23.1%
Nothing announced by JSPR that day or the session before.
- 26 Jun 2026-23.0%
Nothing announced by JSPR that day or the session before.
- 1 Jun 2026-35.6%
- 15 Apr 2026+12.6%
Nothing announced by JSPR that day or the session before.
- 13 Apr 2026+14.5%
Nothing announced by JSPR that day or the session before.
Share of unusual movement by asset
For each asset, the share of JSPR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | KITMonoclonal antibody | AsthmaChronic Spontaneous Urticaria |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $5.1M | $7.7M | $2.8M-$6.9M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $5.8M | $15M | $1.2M-$15M operating cash flow | report ↗ |
| 2025-Q3 | — | $14M | $51M | $19M-$17M operating cash flow | report ↗ |
| 2025-Q2 | — | $21M | $40M | $27M-$15M operating cash flow | report ↗ |
| 2025-Q1 | — | $16M | $49M | $21M-$23M operating cash flow | report ↗ |
| 2024-Q3 | — | $14M | $93M | $19M-$14M operating cash flow | report ↗ |
| 2024-Q2 | — | $11M | $107M | $15M-$12M operating cash flow | report ↗ |
| 2024-Q1 | — | $10M | $119M | $14M-$16M operating cash flow | report ↗ |
| 2023-Q3 | — | $15M | $104M+ $3.4M short-term inv. | $18M-$12M operating cash flow | report ↗ |
| 2023-Q2 | — | $13M | $116M+ $3.2M short-term inv. | $16M-$13M operating cash flow | report ↗ |
| 2023-Q1 | — | $9.8M | $130M | $14M-$10M operating cash flow | report ↗ |
| 2022-Q3 | — | $9.0M | $51M | $12M-$9.6M operating cash flow | report ↗ |
| 2022-Q2 | — | $8.1M | $61M | $10M-$9.4M operating cash flow | report ↗ |
| 2022-Q1 | — | $8.2M | $71M | $2.2M-$14M operating cash flow | report ↗ |
| 2021-Q3 | — | $7.2M | $101M | $3.4M-$18M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $63M | $29M | $19M-$77M operating cash flow | report ↗ |
Jasper Therapeutics reported fiscal-year 2025 results, with research and development expense of $63.1M, up 13.0% YoY from $55.82M, and cash and cash equivalents of $28.7M at December 31, 2025. Revenue was not disclosed, and the company reported a net loss of $75.8M for the year.
The company stated it remains on track to commence patient enrollment in the Phase 2b portion of its planned Phase 2b/3 study in chronic spontaneous urticaria in the second half of 2026, pending capital availability. Clinical updates included positive BEACON study data, with 67% of additional patients in Cohort 9.1 achieving a complete response at 12 weeks and 75% of open-label extension participants achieving complete response or well-controlled disease, as well as positive preliminary ETESIAN asthma data. Jasper also announced the completion of an internal investigation into the anomalous July 2025 BEACON data, which found no issues with the drug product, and appointed Jeet Mahal as Chief Executive Officer.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-07-31 | Shizuru Judith Anne · director | Award / grant (derivative) | 7,500 | — | — | Form 4 |
| 2026-07-31 | EMSTER KURT VON · director | Award / grant (derivative) | 7,500 | — | — | Form 4 |
| 2026-07-31 | Crutcher Patrick J · director | Award / grant (derivative) | 7,500 | — | — | Form 4 |
| 2026-07-31 | Lucas Svetlana · director | Award / grant (derivative) | 7,500 | — | — | Form 4 |
| 2026-07-31 | WIGGANS THOMAS G · director | Award / grant (derivative) | 7,500 | — | — | Form 4 |
| 2026-07-20 | Ros Matthew E · Chief Operating Officer | Open-market purchase (derivative) | 881 | — | — | Form 4 |
| 2026-07-20 | Crutcher Patrick J · director | Open-market purchase (derivative) | 888 | — | — | Form 4 |
| 2026-07-16 | Crutcher Patrick J · director | Award / grant (derivative) | 15,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 58 reporting institutions held 15.8M shares ($13.8M, 47.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Velan Capital Investment Management LP | 2,668,395 | $2.3M |
| 2 | MILLENNIUM MANAGEMENT LLC | 1,617,531 | $1.4M |
| 3 | ACORN CAPITAL ADVISORS, LLC | 1,411,492 | $1.2M |
| 4 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 1,352,106 | $1.2M |
| 5 | MORGAN STANLEY | 1,333,420 | $1.2M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 1,172,597 | $1.0M |
| 7 | Rock Springs Capital Management LP | 1,100,726 | $964K |
| 8 | Carlyle Group Inc. | 1,066,189 | $934K |
| 9 | BOOTHBAY FUND MANAGEMENT, LLC | 582,751 | $511K |
| 10 | Lion Point Capital, LP | 465,000 | $407K |
| 11 | JACOBS LEVY EQUITY MANAGEMENT, INC | 322,273 | $282K |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 317,677 | $278K |
| 13 | BANK OF AMERICA CORP /DE/ | 293,259 | $257K |
| 14 | Soleus Capital Management, L.P. | 276,312 | $242K |
| 15 | BlackRock, Inc. | 242,061 | $212K |